Novartis: Sandoz strikes partnership with India's Biocon
(CercleFinance.com) - Novartis' Sandoz biosimilar unit has struck a partnership with India's Biocon to develop and market immunology and oncology drugs.
Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals.
They will also have an arrangement to share costs and profits: Sandoz will lead marketing in North America and Europe, while Biocon will lead marketing in the rest of the world.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals.
They will also have an arrangement to share costs and profits: Sandoz will lead marketing in North America and Europe, while Biocon will lead marketing in the rest of the world.
Copyright (c) 2018 CercleFinance.com. All rights reserved.